| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.1 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.071 | 0.1 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.1 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.072 | 0.1 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.1 |